Мы предлагаем Клиентам и Партнерам получить последнюю информацию о компании ARS и узнать об избранных новостях из сферы разработок фармацевтических и биологических препаратов, а также запланировать встречу на конференции с представителями ARS с целью детально в личной беседе обсудить потенциальные и текущие проекты.
ARS gains a new contract to conduct a multicenter prospective randomized double-blind placebo-controlled parallel phase III clinical study of medicines treating pain syndrome. 200 patients will be randomized at eight sites.
ARS Business Development Director attended the Russian pharma event held at ExpoForum in April 2019. Several face-to-face meetings with the international pharmaceutical companies were conducted at the conference.
ARS sings an agreement with a Russian company to register its fixed combination of Chlorphenamine 2 mg + Paracetamol 500 mg + Phenylephrine 10 mg + Caffeine 30 mg in tablets. The medicine is a full analogue of Rinza® that is getting the status of a twenty-year-old drug in Russia and, therefore, the generic can be licensed without performing a local bioequivalence study.
ARS signed an agreement for conducting a number of local bioequivalence studies of generics treating diabetes mellitus type II. ARS is responsible for medical writing, regulatory, clinical and analytical parts as well as final CSR preparation.
We wish our Partners and Colleagues health, prosperity, good fortune, and progress in 2019!
The ARS CRO as well its partnering BE Unit and PK lab have been qualified by the external auditor for conducting series of local bioequivalence clinical trials sponsored by the EU pharmaceutical company.
ARS signed an agreement with the Russian pharmaceutical company on medical writing services, namely clinical study essential documents development for six local bioequivalence clinical research projects.
ARS signed a new agreement with its current Client to conduct a bioequivalence clinical trial for Posaconazole suspension.
ARS signed the agreement to prepare the drug safety update report (DSUR) for submitting to the Federal Service for Surveillance in Healthcare (Roszdravnadzor). The report will be developed by the ARS pharmacovigilance team within the current Phase III gynecology clinical research project sponsored by the leading Russian pharmaceutical company.
ARS conducted a contract with the Russian pharmaceutical company developing generic drugs. The agreement includes ARS assistance with the marketing authorization of the three products in Russia.